FIELD: biotechnology.
SUBSTANCE: invention relates to the use of a new combination of antibodies. The application involves the use of a first antibody molecule that specifically binds FcγRIIb through its Fab region but lacks an Fc region or has reduced binding to Fc receptorsγ via its Fc region, for use in a combination with the second antibody molecule that specifically binds to a receptor present on an immune cell.
EFFECT: invention is effective for the treatment of FcγRIIb-negative cancer in patients.
33 cl, 10 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| FcγRIIB RECEPTOR ANTIBODIES AND APPLICATION THEREOF | 2005 |
|
RU2404991C2 |
| MEDICINES, APPLICATIONS AND METHODS | 2015 |
|
RU2712283C2 |
| ANTIGEN-BINDING MOLECULE FOR ACCELERATING ANTIGEN LOSS | 2012 |
|
RU2772771C1 |
| METHOD OF CHANGING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2799423C1 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| TRISPECIFIC BINDING MOLECULES, WHICH SPECIFICALLY BIND ANTIGENS OF A VARIETY OF MALIGNANT TUMORS, AND METHODS OF USING THEM | 2015 |
|
RU2718692C2 |
| HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
